WO2006050472A3 - Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids - Google Patents

Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids Download PDF

Info

Publication number
WO2006050472A3
WO2006050472A3 PCT/US2005/039872 US2005039872W WO2006050472A3 WO 2006050472 A3 WO2006050472 A3 WO 2006050472A3 US 2005039872 W US2005039872 W US 2005039872W WO 2006050472 A3 WO2006050472 A3 WO 2006050472A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
aminopropylphosphonous
analogs
prodrugs
aminopropylphosphinic
Prior art date
Application number
PCT/US2005/039872
Other languages
French (fr)
Other versions
WO2006050472A2 (en
Inventor
Mark A Gallop
Original Assignee
Xenoport Inc
Mark A Gallop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc, Mark A Gallop filed Critical Xenoport Inc
Publication of WO2006050472A2 publication Critical patent/WO2006050472A2/en
Publication of WO2006050472A3 publication Critical patent/WO2006050472A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids R—P(OH)2; Thiophosphonous acids including RHP(=O)(OH); Derivatives thereof
    • C07F9/4808—Phosphonous acids R—P(OH)2; Thiophosphonous acids including RHP(=O)(OH); Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
    • C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl

Abstract

Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3­aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3­aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3­aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-­aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.
PCT/US2005/039872 2004-11-03 2005-11-03 Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids WO2006050472A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62487304P 2004-11-03 2004-11-03
US60/624,873 2004-11-03

Publications (2)

Publication Number Publication Date
WO2006050472A2 WO2006050472A2 (en) 2006-05-11
WO2006050472A3 true WO2006050472A3 (en) 2006-08-03

Family

ID=35929891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039872 WO2006050472A2 (en) 2004-11-03 2005-11-03 Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids

Country Status (2)

Country Link
US (2) US7494985B2 (en)
WO (1) WO2006050472A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ES2405329T3 (en) 2003-12-30 2013-05-30 Xenoport, Inc. Synthesis of acyloxyalkyl carbonate prodrugs and intermediates thereof
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd
CN101743011A (en) * 2007-07-25 2010-06-16 阿斯利康(瑞典)有限公司 The use of (3-amino-2-fluoropropyl) phosphinic acid for treatment of nerd
FR2934267B1 (en) * 2008-07-23 2010-08-13 Pharmaleads AMINOPHOSPHINIC DERIVATIVES USEFUL IN THE TREATMENT OF PAIN
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
EP2410009B1 (en) 2010-07-21 2013-03-06 Sika Technology AG Polymerization regulator

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281747A (en) * 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5567840A (en) * 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
WO2001042252A1 (en) * 1999-12-09 2001-06-14 Astrazeneca Ab New aminopropylphosphinic acids
WO2001054481A2 (en) * 2000-01-28 2001-08-02 Rohm And Haas Company Enhanced propertied pharmaceuticals
WO2002100870A1 (en) * 2001-06-08 2002-12-19 Astrazeneca Ab New napsylate salts ii
WO2002100871A1 (en) * 2001-06-08 2002-12-19 Astrazeneca Ab New compounds useful in reflux disease
WO2002100869A1 (en) * 2001-06-08 2002-12-19 Astrazeneca Ab New napsylate salts i

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
DE2128012A1 (en) 1971-06-05 1972-12-14 Cassella Farbwerke Mainkur Ag Process for the production of polymers
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (en) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Oral dosage form
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4126684A (en) 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
GB8728483D0 (en) 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
US5300679A (en) 1987-12-04 1994-04-05 Ciba-Geigy Corporation Substituted propane-phosphinic acid compounds
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
JP2675142B2 (en) * 1989-06-12 1997-11-12 日本エランコ株式会社 Capsule sealing machine
US5006560A (en) 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
IL98502A (en) 1990-06-22 1998-04-05 Ciba Geigy Ag Aminoalkane phosphinic acid derivatives, process for their preparation and pharmaceutical compositions containing them
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0767174A1 (en) 1991-11-21 1997-04-09 Ciba-Geigy Ag Novel aminoalkanephosphinic acids and their salts
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
AU662404B2 (en) 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
GB9308430D0 (en) 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
SE9603408D0 (en) 1996-09-18 1996-09-18 Astra Ab Medical use
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
FR2779651B1 (en) 1998-06-16 2001-04-20 Gattefosse Ets Sa PROCESS FOR THE MANUFACTURE OF SUSTAINED RELEASE TABLETS OF ACTIVE INGREDIENT (S) HAVING ZERO-SIZE DISSOLUTION KINETICS
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
GB9906882D0 (en) 1999-03-25 1999-05-19 Novartis Ag Organic compounds
IT1313585B1 (en) 1999-07-30 2002-09-09 Neuroscienze S C A R L USE OF GABAB RECEPTOR AGONISTS FOR THE MAINTENANCE THERAPY OF NICOTINE ABSTINENCE IN NICOTINO-EMPLOYEES.
IT1319275B1 (en) 1999-10-08 2003-09-26 Neuroscienze S C A R L USE OF BACLOFEN IN THE TREATMENT OF ETHANOL ABSTINENCE.
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
EP1372620A2 (en) 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
AR033779A1 (en) 2001-06-08 2004-01-07 Astrazeneca Ab USEFUL COMPOUNDS IN REFLUX DISEASE
US6833140B2 (en) 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
CA2452738C (en) 2001-07-04 2011-06-14 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20030162754A1 (en) 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
SE0201940D0 (en) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0201939D0 (en) 2002-06-20 2002-06-20 Astrazeneca Ab New combination
US7319110B2 (en) * 2002-09-19 2008-01-15 Solvay Pharmaceuticals B.V. 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ES2405329T3 (en) 2003-12-30 2013-05-30 Xenoport, Inc. Synthesis of acyloxyalkyl carbonate prodrugs and intermediates thereof
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7566738B2 (en) 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281747A (en) * 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5461040A (en) * 1989-05-13 1995-10-24 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5567840A (en) * 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
WO2001042252A1 (en) * 1999-12-09 2001-06-14 Astrazeneca Ab New aminopropylphosphinic acids
WO2001054481A2 (en) * 2000-01-28 2001-08-02 Rohm And Haas Company Enhanced propertied pharmaceuticals
WO2002100870A1 (en) * 2001-06-08 2002-12-19 Astrazeneca Ab New napsylate salts ii
WO2002100871A1 (en) * 2001-06-08 2002-12-19 Astrazeneca Ab New compounds useful in reflux disease
WO2002100869A1 (en) * 2001-06-08 2002-12-19 Astrazeneca Ab New napsylate salts i

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FROESTL W ET AL: "Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 17, 1995, pages 3297 - 3312, XP002043375, ISSN: 0022-2623 *
ZHONG L ET AL: "Synthesis of (alkoxycarbonyloxy)methyl, (acyloxy)methyl and (oxodioxolenyl)methyl carbamates as bioreversible prodrug moieties for amines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 22, 18 November 1997 (1997-11-18), pages 2909 - 2912, XP004136555, ISSN: 0960-894X *

Also Published As

Publication number Publication date
US7494985B2 (en) 2009-02-24
US7935686B2 (en) 2011-05-03
US20090124582A1 (en) 2009-05-14
WO2006050472A2 (en) 2006-05-11
US20060111325A1 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
WO2006050472A3 (en) Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2005019163A3 (en) Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2007002013A3 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
CY1121350T1 (en) ORAL PHARMACEUTICAL FORMS OF CYTIDINE ANALOGS AND METHODS OF USING THEM
WO2006050471A3 (en) Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
MX2007005306A (en) Gabapentin prodrug sustained release oral dosage forms.
WO2007103435A3 (en) Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
WO2006037982A3 (en) Modulators of crth2 receptor activity for the treatment of prostaglandin d2 mediated diseases
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
NO20082124L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2008061226A3 (en) Sustained-release formulations of topiramate
WO2006021000A3 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon
WO2006042034A8 (en) Salt and crystalline forms thereof of a drug
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2008023258A8 (en) Piperidine derivatives
MY145329A (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
WO2005002582A3 (en) Trp-p8 active compounds and therapeutic treatment methods
WO2008013860A3 (en) Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2007073560A3 (en) Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
WO2006079077A3 (en) Use of diltiazem or analogs thereof as modulators of ghrelin receptor
WO2008002567A3 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05824624

Country of ref document: EP

Kind code of ref document: A2